Dr Jacinta Perram

Dr Jacinta Perram

Senior Lecturer

MBBS(Hons), BA(Psych), BMedSc, MPH, FRACP, FRCPA, ECFMG Cert.


Medicine & Health
School of Clinical Medicine

Dr Perram is a Clinical and Laboratory Haematologist and Clinical Researcher. She works in malignancy and transplant haematology, with experience in CAR T therapy. Dr Perram has a special interest in myelofibrosis, and transplant for autoimmune disease, as well as long term complications following transplant. 

Before pursuing her medical career, Dr Perram worked in Clinical Research management in the Pharmaceutical Industry and is passionate about ensuring access for her patients to novel therapies through a strong clinical trials program.

+61 2 9355 5656
The Kinghorn Cancer Centre 370 Victoria Street DARLINHURST NSW 2010


Perram J et al ANZTCT Position Statement: COVID-19 Management in Haematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T cell patients. IMJ 2023, 53(1): 119-125.

Perram J, Ross D, McLornan D, Gowin K, Kroger N, Gupta V, Lewis C, Gagelmann N, Hamad N. Innovative Strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. Am J Hematol, 2022 Nov, 97(11):1464-1477.

Anderson S, Perram J, Nelson A, Matthews S, Gou M, Hoy PJ. Pregnancy and assisted reproductive technology use in Australian female transfusion-dependent haemoglobinopathy patients: a 20-year retrospective analysis. IMJ 2023 Jul, online ahead of print.

Perram J… Moore J. Alternative donor stem cell transplantation provides sustained disease free survival in haematologic malignancies: a single centre retrospective analysis from 2003-2014. Under review, IMJ 2022

Perram J, Vanguru V, Ackerman L, Blayney B. Red cell transfusion in alloimmunised allogeneic stem cell transplant patients. Pathology 2022 Aug; 54(5): 629-631.

Perram J, Hamad N, Schoemans H. First do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation.  Lancet Haematology, 2022 Jul; 9(7): e476-477.

Perram J, Hamad N.  Not all mismatches are created equal: Refining TCE based HLA-DPB1 algorithms and the importance of alloreactivity direction.  Haematologica, April 2022, Vol 107(4).

Perram J, Blayney B, Ackerman L, Beig A, Khoo L.  Solid Phase Antibody Screening in the Presence of anti-CD38 Monoclonal Antibodies: A Potential Alternative to Avoid Interference.  Pathology 2020 June, 52(4): 492-494.

Perram J, McKenzie C, Rasko J. Multinucleated Giant Plasma Cells in a New Diagnosis of Multiple Myeloma.  Pathology 2019 Vol 51(S1) – S42.

Perram J, O’Dwyer E, Holloway C.  Use of Dabigatran with Antiretrovirals. HIV Medicine, 2019 May 20(5): 344-346.

Perram J, Gibson J. How To Treat: Abnormalities in the Full Blood Count. Australian Doctor, 2018.

West T, Perram J, Holloway C. Use of Direct Oral Anticoagulants for Treatment of Atrial Fibrillation in Patients with HIV: a review. Current Opinions in HIV and AIDS, 2017. 12(6):554-560.

Perram J, Dix C, Gibson J. How To Treat: Multiple Myeloma. Australian Doctor, 2017.

Fortier E, Alavi M, Bruneau J, Micallef M, Perram J et al. Depression, anxiety and stress among people with chronic hepatitis C infection and a history of injecting drug use in New South Wales, Australia: The ETHOS Study. Journal of Addiction Medicine 2016.

Ni Chroinin D, Neto H, Xiao D, Sandhu A, Brazel C, Farnham N, Perram J, Roach T, Sutherland E, Day R, Beveridge A. Potentially inappropriate medications (PIMs) in older hospital in-patients: Prevalence, contribution to hospital admission and documentation of rationale for continuation. Australia J Ageing, 2016 March

Perram J, Joseph J, Holloway C. Novel Oral Anticoagulants and HIV: dabigatran use with antiretrovirals.  BMJ Case Reports, 2015 online publication

Perram J, Estell J. A novel case of symptomatic BK viraemia in a patient undergoing treatment for Hodgkin Lymphoma. Case Reports in Infectious Disease, 2014. Vol June